ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation antibody-drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology. These proprietary PBD-based ADCs are expected to provide a novel way to treat hematological cancers and solid tumors, address significant unmet medical needs, and improve the lives of patients with cancer. Our mission is to confront cancer with the full potential of our science to bring unique, targeted therapies and hope to patients and their families.
Our mission, vision, and values form the foundation of ADC Therapeutics and provide guidance for all future endeavors. These foundational pillars are also a meaningful expression of the company’s dedication to helping those with difficult-to-treat cancers. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London (R&D), New Jersey (Clinical and Commercial), and the San Francisco Bay Area (CMC).
Total Funding: $691.6 M
Funding Stage: Funded
Business Stage: Scaling Up
Market: B2B
Company Size: 251 to 500
Founded: 2011
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at ADC Therapeutics
Cancer Biologist - FTC
London, England
Senior Scientist, Bioassay Development
Remote, Remote
Associate Director, Pharmacovigilance Systems
New Providence, New Jersey
Project Director
New Providence, New Jersey
Project Manager
London, England
